None listed
Conditions
Interventions
Drug : The dosage of clarithromycin for the treatment regimen for H. pylori eradication therapy will be adjusted as follows
1) study group
Dexilant 60mg , ampicillin 500mg, clarithromycin SR 250 mg
2) control group: Dexilant 60mg , ampicillin 500mg, clarithromycin SR 500 mg
Sponsors
Chonnam National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients eligible for eradication therapy were selected based on the following criteria after undergoing gastroscopy and H. pylori PCR testing, confirming the absence of clarithromycin resistance gene mutations (A2143G, A2142G): 1) Aged between 18 and 75 years 2) Positive for H. pylori PCR 3) No A2143G or A2142G mutations 4) History of conditions such as atrophic gastritis, peptic ulcer, low-grade MALT lymphoma, functional dyspepsia, idiopathic thrombocytopenic purpura, iron 5) deficiency anemia, hyperplastic polyps, history of endoscopic resection for gastric cancer or adenoma, or family history of gastric cancer 6) Patients who voluntarily signed the consent form.
Exclusion criteria
Exclusion criteria: 1) Previous experience with eradication therapy 2) History of surgeries that may affect gastric acid secretion or plans for such surgeries 3) Conditions associated with increased gastric acid secretion (e.g., Zollinger-Ellison syndrome) 4) Gastric outlet obstruction 5) Pregnant or breastfeeding women 6) History of allergies to the study medication 7) Patients unwilling to undergo eradication therapy 8) Patients taking contraindicated medications (e.g., atazanavir, nelpivirine, or rilpivirine) or those with hypersensitivity or intolerance to these medications 9) Renal impairment (e-GFR three times the upper limit of normal) 10) Patients with gastrointestinal bleeding 11) Patients showing abnormal ECG results, such as QT prolongation 12) Patients with central nervous system infections, infectious mononucleosis, or electrolyte imbalances (e.g., hypokalemia, hypomagnesemia) 13) Patients who do not agree to use appropriate contraception during the study period, either personally or with their partner.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The eradication rate of H. pylori | — |
Secondary
| Measure | Time frame |
|---|---|
| Medication adherence and medication side effects | — |
Countries
Korea, Republic of
Contacts
Public ContactSeon-Young Park
Chonnam National University Hospital
Outcome results
None listed